BioSpace News Archive

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that following a pre-specified interim futility analysis for the ongoing Phase 3 SIENDO study

ESSA Pharma Inc. (Nasdaq: EPIX) , a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Evercore ISI 3 rd Annual HealthCONx Conference.

Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Piper Sandler 32 nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 at 8:30am ET. ABOUT

LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that members of the executive management team will participate in a virtual fireside chat at the 3 rd Annual Evercore ISI HealthCONx Conference on Thursday, Dec. 3 at 1:50 p.m. ET. A live webcast of the presentation will be available via the company website at www.LabC

Abpro Corporation today announced the expansion of its scientific advisory board with additions of infectious disease drug development leaders

Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not initiate the EQUINOX Phase 3 clinical trial to evaluate itolizumab in hospitalized COVID-19 patients at this time.

On August 21, 2020, Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Horizon Therapeutics plc announced that the Company will participate in the following conferences in December:

Halberd Corporation Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV.

Transparency Market Research has published a new report on the global vascular injury treatment market.